SCHEMBL3696289

SCHEMBL3696289

COC(=O)C1=C(c2ccc(C)cc2F)CCN(C(=O)OC(C)(C)C)C1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.43
ESR2 Q92731 1/20 0.42
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MKNK1 Q9BUB5 4/20 0.38
GPR119 Q8TDV5 2/20 0.37
CHRM2 P08172 2/20 0.37
CHRM4 P08173 2/20 0.37
CHRM5 P08912 2/20 0.37
CHRM1 P11229 2/20 0.37
CHRM3 P20309 2/20 0.37
KMT2A Q03164 2/20 0.37
CDK9 P50750 1/20 0.36
F13A1 P00488 1/20 0.36
TGM2 P21980 1/20 0.36
TGM1 P22735 1/20 0.36
MEN1 O00255 1/20 0.36
GRM5 P41594 2/20 0.36
GRM1 Q13255 2/20 0.36
MAPT P10636 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4219188 0.91 MKNK1 (0.45) NR1H2ESR2MKNK1GPR119CDK9
SCHEMBL3693556 0.89 ESR2 (0.44) NR1H2ESR2LMNANPSR1MKNK1
SCHEMBL951478 0.81 NR1H2 (0.47) NR1H2ESR2MKNK1CHRM2CHRM4
SCHEMBL951733 0.81 NR1H2 (0.47) NR1H2ESR2GPR119CHRM2CHRM4
SCHEMBL3648553 0.80 ESR2 (0.45) NR1H2ESR2MKNK1GPR119CDK9
SCHEMBL6418231 0.79 CHRM5 (0.59) NR1H2ESR2GPR119CHRM2CHRM4
SCHEMBL1750511 0.78 ESR2 (0.53) NR1H2ESR2CHRM2CHRM4CHRM5
SCHEMBL2243902 0.78 ADORA1 (0.46) NR1H2ESR2LMNANPSR1GPR119
SCHEMBL3197517 0.77 SLC6A3 (0.54) NR1H2ESR2NPSR1MKNK1CHRM2
SCHEMBL8253723 0.77 ESR2 (0.52) NR1H2ESR2MKNK1CHRM2CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188266-B1 Novel piperazine amide derivatives HOFFMANN LA ROCHE (CH) 2012-10-17 EP disclosed
US-8288541-B2 Piperazine amide derivatives HOFFMANN-LA ROCHE INC. (US) 2012-10-16 US disclosed
CN-101778831-A Novel piperazine amide derivatives HOFFMANN LA ROCHE 2010-07-14 CN disclosed
EP-2188266-A2 NOVEL PIPERAZINE AMIDE DERIVATIVES F. Hoffmann-Roche AG (CH) 2010-05-26 EP disclosed
WO-2009021868-A2 NOVEL PIPERAZINE AMIDE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-02-19 WO disclosed
US-20090048264-A1 PIPERAZINE AMIDE DERIVATIVES HOFFMANN-LA ROCHE, INC. 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048264-A1 PIPERAZINE AMIDE DERIVATIVES NR1H2, NR1H3, NR1I2 NR1H2 1/4885ESR2 36/4885LMNA 2374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.